Evidence map›Paper›PMID 36139058›Full record

ArticleBiomolecules2022

Polyphenolic Compounds Inhibit Osteoclast Differentiation While Reducing Autophagy through Limiting ROS and the Mitochondrial Membrane Potential.

Dipranjan Laha, Jaganmay Sarkar, Jyotirindra Maity, Asmita Pramanik, Md Sariful Islam Howlader, Derek Barthels, Hiranmoy Das

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Ellagic acid alleviates PMToxicology research · 2025
    Article
  12. Review
  13. Review
  14. Review
  15. Lysosomal biogenesis and function in osteoclasts: a comprehensive review.Frontiers in cell and developmental biology · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Dipranjan LahaDepartment of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA.
Jaganmay SarkarDepartment of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA.ORCID 0000-0003-1073-4537
Jyotirindra MaityDepartment of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA.
Asmita PramanikDepartment of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA.
Md Sariful Islam HowladerDepartment of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA.ORCID 0000-0002-5354-5827
Derek BarthelsDepartment of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA.ORCID 0000-0003-2089-7268
Hiranmoy DasDepartment of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA.ORCID 0000-0002-3343-0096
Texas Tech University · US

Funding

Myeloid KLF2 regulation mechanisms in rheumatoid arthritisR01AR068279 · NIAMS · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI DAS, HIRANMOY · 2016 to 2022
$1.7M
Regenerative Therapy for Corneal Endothelial Dystrophies and InjuriesR42EY031196 · NEI · RASHMIVU, LLC · PI DAS, HIRANMOY · 2020 to 2020
$300k
Corneal Endothelial Stem Cells for Treatment of Corneal Endothelial DystrophiesR41EY024217 · NEI · RASHMIVU, LLC · PI DAS, HIRANMOY · 2014 to 2016
$268k
Nanofiber Expanded CD34+ Stem Cells for Osteoporosis TherapyR41AG057242 · NIA · HNB THERAPEUTICS, LLC · PI DAS, HIRANMOY · 2018 to 2018
$225k
NEI NIH HHS R41 EY024217NEI NIH HHS R42 EY031196NIAMS NIH HHS R01 AR068279NIA NIH HHS R41 AG057242
6 · The paper itself

Abstract

Polyphenolic compounds are a diverse group of natural compounds that interact with various cellular proteins responsible for cell survival, differentiation, and apoptosis. However, it is yet to be established how these compounds interact in myeloid cells during their differentiation and the molecular and intracellular mechanisms involved. Osteoclasts are multinucleated cells that originate from myeloid cells. They resorb cartilage and bone, maintain bone homeostasis, and can cause pathogenesis. Autophagy is a cellular mechanism that is responsible for the degradation of damaged proteins and organelles within cells and helps maintain intracellular homeostasis. Imbalances in autophagy cause various pathological disorders. The current study investigated the role of several polyphenolic compounds, including tannic acid (TA), gallic acid (GA), and ellagic acid (EA) in the regulation of osteoclast differentiation of myeloid cells. We demonstrated that polyphenolic compounds inhibit osteoclast differentiation in a dose-dependent manner. Quantitative real-time PCR, immunocytochemistry, and western blotting revealed that osteoclast markers, such as NFATc1, Cathepsin K, and TRAP were inhibited after the addition of polyphenolic compounds during osteoclast differentiation. In our investigation into the molecular mechanisms, we found that the addition of polyphenolic compounds reduced the number of autophagic vesicles and the levels of LC3B, BECN1, ATG5, and ATG7 molecules through the inactivation of Akt, thus inhibiting the autophagy process. In addition, we found that by decreasing intracellular calcium and decreasing ROS levels, along with decreasing mitochondrial membrane potential, polyphenolic compounds inhibit osteoclast differentiation. Together, this study provides evidence that polyphenolic compounds inhibit osteoclast differentiation by reducing ROS production, autophagy, intracellular Ca

Indexed as

OsteoclastsRANK LigandAutophagyCalciumCathepsin KCell DifferentiationEllagic AcidGallic AcidMembrane Potential, MitochondrialProto-Oncogene Proteins c-aktReactive Oxygen SpeciesTanninsCalciumCathepsin KEllagic AcidGallic AcidProto-Oncogene Proteins c-aktRANK LigandReactive Oxygen SpeciesTanninsautophagyellagic acidgallic acidmitochondrial membrane potentialosteoclast differentiationROStannic acid

Identifiers

PMID36139058
PMCPMC9496366
OpenAlexW4294132928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.